You are here

  • Home
  • Archive
  • Volume 11, Issue 12
  • XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer

Article metrics

Article menu
Oncolytic and local immunotherapy
Original research
XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4 monoclonal antibody, demonstrates tumor-growth inhibition and tumor-selective pharmacodynamics in mouse models of cancer

 

Online download statistics by month:

Online download statistics by month: December 2023 to August 2025

AbstractFullPdf
Dec 2023798801158
Jan 2024453455234
Feb 202422222267
Mar 2024295300135
Apr 2024246246100
May 202427527457
Jun 202416416466
Jul 202445946363
Aug 202411011045
Sep 202415915970
Oct 202423023098
Nov 202421822482
Dec 202419720154
Jan 202518118167
Feb 202529329477
Mar 202518318364
Apr 202517117167
May 202516917167
Jun 202512912945
Jul 2025110
Aug 2025110
Total495449801616